Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987;33(3):227-30.
doi: 10.1007/BF00637553.

Enoxacin--a potent inhibitor of theophylline metabolism

Affiliations

Enoxacin--a potent inhibitor of theophylline metabolism

J Beckmann et al. Eur J Clin Pharmacol. 1987.

Abstract

The mechanism of the theophylline-enoxacin interaction has been studied in six healthy subjects. Theophylline 250 mg was administered p.o., twice daily for 11 days in a sustained release dosage form. On the 4th day of treatment, blood samples were taken every 2 h and urine was collected over 1 dose interval. From Days 5 to 11 coated tablets of enoxacin 400 mg b.i.d. were coadministered. On Day 11 blood and urine were collected as on Day 4. The mean plasma theophylline concentration rose from 4.4 to 15.1 mg/l, corresponding to a 73.6% reduction in total clearance. The urinary excretion of unchanged theophylline increased from 12.7 to 35.3%, whereas the production of metabolites was reduced (1-demethylation 81.4%; 3-demethylation 83.1%, 8-hydroxylation 74.6%). The results indicate that the theophylline-enoxacin interaction may be due to inhibition of the cytochrome P-450 isozymes responsible for theophylline metabolism. Unexpectedly, the renal clearance of theophylline metabolites was found to be drastically reduced when enoxacin was coadministered. This led to unchanged or even to elevated plasma levels of the metabolites. The mechanism of this interaction is still to be elucidated, but it may be due to competition for renal tubular secretion.

PubMed Disclaimer

References

    1. Lancet. 1984 Jul 14;2(8394):108-9 - PubMed
    1. Clin Pharmacol Ther. 1982 Mar;31(3):358-69 - PubMed
    1. Dtsch Med Wochenschr. 1986 Sep 26;111(39):1500 - PubMed
    1. Br J Clin Pharmacol. 1983 Jan;15(1):117-9 - PubMed
    1. Infection. 1986;14 Suppl 1:S67-9 - PubMed

LinkOut - more resources